Publikationen, an denen er mitarbeitet Javier Martín Broto (9)

2020

  1. Prognostic impact of let-7e microRNA and its target genes in localized high-risk intestinal GIST: A spanish group for research on sarcoma (GEIS) study

    Cancers, Vol. 12, Núm. 10, pp. 1-18

2018

  1. Nilotinib as coadjuvant treatment with doxorubicin in patients with sarcomas: A phase i trial of the Spanish group for research on sarcoma

    Clinical Cancer Research, Vol. 24, Núm. 21, pp. 5239-5249

2017

  1. Disruption of TCF/b-Catenin binding impairs Wnt signaling & induces apoptosis in soft tissue sarcoma cells

    Molecular Cancer Therapeutics, Vol. 16, Núm. 6, pp. 1166-1176

2015

  1. RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas

    Cancer Investigation, Vol. 33, Núm. 9, pp. 440-450

  2. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

    Annals of Surgical Oncology, Vol. 22, Núm. 9, pp. 2948-2957

2014

  1. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: An ISG/GEIS study

    Molecular Cancer Therapeutics, Vol. 13, Núm. 1, pp. 249-259

2012

  1. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas

    PLoS ONE, Vol. 7, Núm. 5

2011

  1. Clinical implications of KIT and PDGFRA in gastrointestinal stromal tumors

    Cancer and Chemotherapy Reviews, Vol. 6, Núm. 4, pp. 209-220

2004

  1. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)

    Journal of Neuro-Oncology, Vol. 70, Núm. 3, pp. 359-370